GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » KORU Medical Systems Inc (NAS:KRMD) » Definitions » Altman Z2-Score

KORU Medical Systems (KORU Medical Systems) Altman Z2-Score : 0.76 (As of Jun. 04, 2024)


View and export this data going back to 1996. Start your Free Trial

What is KORU Medical Systems Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

KORU Medical Systems has a Altman Z2-Score of 0.76, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for KORU Medical Systems's Altman Z2-Score or its related term are showing as below:

KRMD' s Altman Z2-Score Range Over the Past 10 Years
Min: 0.76   Med: 10.88   Max: 16.58
Current: 0.76

During the past 13 years, KORU Medical Systems's highest Altman Z2-Score was 16.58. The lowest was 0.76. And the median was 10.88.


KORU Medical Systems Altman Z2-Score Historical Data

The historical data trend for KORU Medical Systems's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KORU Medical Systems Altman Z2-Score Chart

KORU Medical Systems Annual Data
Trend Feb14 Feb15 Feb16 Feb17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.42 15.75 12.06 4.10 1.30

KORU Medical Systems Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.38 3.93 3.48 1.30 0.76

Competitive Comparison of KORU Medical Systems's Altman Z2-Score

For the Medical Instruments & Supplies subindustry, KORU Medical Systems's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KORU Medical Systems's Altman Z2-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, KORU Medical Systems's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where KORU Medical Systems's Altman Z2-Score falls into.



KORU Medical Systems Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

KORU Medical Systems's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.5318+3.26*-0.9181+6.72*-0.3172+1.05*2.2806
=0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2024:
Total Assets was $27.50 Mil.
Total Current Assets was $19.48 Mil.
Total Current Liabilities was $4.85 Mil.
Retained Earnings was $-25.25 Mil.
Pre-Tax Income was -1.936 + -2.021 + -1.669 + -3.096 = $-8.72 Mil.
Interest Expense was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Liabilities was $8.38 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(19.479 - 4.853)/27.501
=0.5318

X2=Retained Earnings/Total Assets
=-25.248/27.501
=-0.9181

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-8.722 - 0)/27.501
=-0.3172

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(19.118 - 0)/8.383
=2.2806

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

KORU Medical Systems has a Altman Z2-Score of 0.76 indicating it is in Distress Zones.


KORU Medical Systems  (NAS:KRMD) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


KORU Medical Systems Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of KORU Medical Systems's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


KORU Medical Systems (KORU Medical Systems) Business Description

Traded in Other Exchanges
N/A
Address
100 Corporate Drive, Mahwah, NJ, USA, 07430
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on home and specialty infusion solutions. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Executives
Manko Joseph M. Jr. 10 percent owner 1717 ARCH STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Kenneth E Miller officer: Chief Commercial Officer 26 MOUNTAINVIEW RD, WARREN NJ 07059
Edward Wholihan director C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTOWN EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Linda M Tharby officer: President and CEO BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Robert Cascella director C/O HOLOGIC, INC., BEDFORD MA 01730
Lafrence Andrew D.c. officer: Chief Financial Officer C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Thomas Edward Adams officer: Interim CFO 524 WOODLAND AVENUE, BRIELLE NJ 08730
Brian Case officer: Chief Technology Officer 424 CYPRUS CIR, LAKE VILLA IL 60046-8629
Shahriar Matin director 96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Donna French director 25 SEARSVILLE COURT, HILLSBOROUGH CA 94010
Donald B Pettigrew officer: Pres./Chief Commercial Officer 7871 ENGEN LOOP, PARK CITY UT 84098
Karen Fisher officer: CFO 24 CARPENTER ROAD, CHESTER NY 10918
Daniel S Goldberger director 24 CARPENTER ROAD, CHESTER NY 10918
R John Fletcher director C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Horton Freedom, L.p. 10 percent owner 1717 ARCH STREET, 37TH FLOOR, PHILADELPHIA PA 19103